Class information for:
Level 1: VORTIOXETINE//LU AA21004//BIS ARYL SULFANYLA MINE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
32254 141 43.2 77%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
11 4 NEUROSCIENCES//CLINICAL NEUROLOGY//NEUROL 1112395
76 3       NEUROSCIENCES//DOPAMINE//SEROTONIN 81359
218 2             SEROTONIN//5 HT1A RECEPTOR//5 HT2A RECEPTOR 20633
32254 1                   VORTIOXETINE//LU AA21004//BIS ARYL SULFANYLA MINE 141

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 VORTIOXETINE authKW 6160008 34% 59% 48
2 LU AA21004 authKW 2829770 10% 93% 14
3 BIS ARYL SULFANYLA MINE authKW 433128 1% 100% 2
4 CNS MED address 433128 1% 100% 2
5 VORTIOXETINE HYDROBROMIDE authKW 433128 1% 100% 2
6 CLIN QUANTITAT PHARMACOL address 389813 2% 60% 3
7 MULTIMODAL ANTIDEPRESSANT authKW 389813 2% 60% 3
8 EXTERNAL SOURCING SCI EXCELLENCE address 384998 3% 44% 4
9 BRINTELLIX authKW 288751 1% 67% 2
10 5 AXIS TEMPLATE authKW 216564 1% 100% 1

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Psychiatry 1968 43% 0% 60
2 Pharmacology & Pharmacy 1355 57% 0% 80
3 Clinical Neurology 602 29% 0% 41
4 Neurosciences 197 23% 0% 33
5 Toxicology 28 5% 0% 7
6 Nursing 27 3% 0% 4
7 Psychology, Clinical 27 4% 0% 5
8 Medicine, Research & Experimental 21 6% 0% 8
9 Food Science & Technology 16 5% 0% 7
10 Chemistry, Analytical 13 6% 0% 8

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CNS MED 433128 1% 100% 2
2 CLIN QUANTITAT PHARMACOL 389813 2% 60% 3
3 EXTERNAL SOURCING SCI EXCELLENCE 384998 3% 44% 4
4 CNS STAT 216564 1% 100% 1
5 CNS STATPHARMACOVIGILANCE 216564 1% 100% 1
6 EQUIPE DEP S ANTIDEP SEURS MED PARIS SU 216564 1% 100% 1
7 INSERM UMR S SANTE MENTALE SANTE PUBL 1178 216564 1% 100% 1
8 INSERMSANTE MENTALE SANTE PUBL U1178 216564 1% 100% 1
9 LANGONE MED BEHAV HLTH PROGRAMSPEARL BARLOW 216564 1% 100% 1
10 MED AFFAIRS MOOD ANXIETY 216564 1% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CNS SPECTRUMS 12782 6% 1% 8
2 EUROPEAN NEUROPSYCHOPHARMACOLOGY 11573 8% 0% 11
3 INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 4418 4% 0% 6
4 NEUROPSYCHIATRIC DISEASE AND TREATMENT 3559 4% 0% 5
5 JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES 3021 2% 0% 3
6 INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY 2944 4% 0% 5
7 RIVISTA DI PSICHIATRIA 2020 1% 0% 2
8 BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 1934 3% 0% 4
9 JOURNAL OF PSYCHOPHARMACOLOGY 1509 3% 0% 4
10 BIOMEDICINE & PHARMACOTHERAPY 869 3% 0% 4

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 VORTIOXETINE 6160008 34% 59% 48 Search VORTIOXETINE Search VORTIOXETINE
2 LU AA21004 2829770 10% 93% 14 Search LU+AA21004 Search LU+AA21004
3 BIS ARYL SULFANYLA MINE 433128 1% 100% 2 Search BIS+ARYL+SULFANYLA+MINE Search BIS+ARYL+SULFANYLA+MINE
4 VORTIOXETINE HYDROBROMIDE 433128 1% 100% 2 Search VORTIOXETINE+HYDROBROMIDE Search VORTIOXETINE+HYDROBROMIDE
5 MULTIMODAL ANTIDEPRESSANT 389813 2% 60% 3 Search MULTIMODAL+ANTIDEPRESSANT Search MULTIMODAL+ANTIDEPRESSANT
6 BRINTELLIX 288751 1% 67% 2 Search BRINTELLIX Search BRINTELLIX
7 5 AXIS TEMPLATE 216564 1% 100% 1 Search 5+AXIS+TEMPLATE Search 5+AXIS+TEMPLATE
8 5HT1B D 216564 1% 100% 1 Search 5HT1B+D Search 5HT1B+D
9 ADVERSE EFFECTS SIDE EFFECTS SAFETY 216564 1% 100% 1 Search ADVERSE+EFFECTS+SIDE+EFFECTS+SAFETY Search ADVERSE+EFFECTS+SIDE+EFFECTS+SAFETY
10 BREO ELLIPTA 216564 1% 100% 1 Search BREO+ELLIPTA Search BREO+ELLIPTA

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 GARNOCK-JONES, KP , (2014) VORTIOXETINE: A REVIEW OF ITS USE IN MAJOR DEPRESSIVE DISORDER.CNS DRUGS. VOL. 28. ISSUE 9. P. 855 -874 30 86% 10
2 GIBB, A , DEEKS, E , (2014) VORTIOXETINE: FIRST GLOBAL APPROVAL.DRUGS. VOL. 74. ISSUE 1. P. 135 -145 27 90% 17
3 AL-SUKHNI, M , MARUSCHAK, NA , MCINTYRE, RS , (2015) VORTIOXETINE: A REVIEW OF EFFICACY, SAFETY AND TOLERABILITY WITH A FOCUS ON COGNITIVE SYMPTOMS IN MAJOR DEPRESSIVE DISORDER.EXPERT OPINION ON DRUG SAFETY. VOL. 14. ISSUE 8. P. 1291 -1304 33 70% 7
4 BALDWIN, DS , CHRONES, L , FLOREA, I , NIELSEN, R , NOMIKOS, GG , PALO, W , REINES, E , (2016) THE SAFETY AND TOLERABILITY OF VORTIOXETINE: ANALYSIS OF DATA FROM RANDOMIZED PLACEBO-CONTROLLED TRIALS AND OPEN-LABEL EXTENSION STUDIES.JOURNAL OF PSYCHOPHARMACOLOGY. VOL. 30. ISSUE 3. P. 242 -252 24 75% 4
5 DE BARTOLOMEIS, A , FAGIOLINI, A , MAINA, G , (2016) VORTIOXETINE IN THE TREATMENT OF MAJOR DEPRESSION.RIVISTA DI PSICHIATRIA. VOL. 51. ISSUE 6. P. 215 -230 42 53% 0
6 CITROME, L , (2014) VORTIOXETINE FOR MAJOR DEPRESSIVE DISORDER: A SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY PROFILE FOR THIS NEWLY APPROVED ANTIDEPRESSANT - WHAT IS THE NUMBER NEEDED TO TREAT, NUMBER NEEDED TO HARM AND LIKELIHOOD TO BE HELPED OR HARMED?.INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. VOL. 68. ISSUE 1. P. 60 -82 24 73% 26
7 KATONA, CL , KATONA, CP , (2014) NEW GENERATION MULTI-MODAL ANTIDEPRESSANTS: FOCUS ON VORTIOXETINE FOR MAJOR DEPRESSIVE DISORDER.NEUROPSYCHIATRIC DISEASE AND TREATMENT. VOL. 10. ISSUE . P. 349 -353 18 90% 11
8 CONNOLLY, KR , THASE, ME , (2016) VORTIOXETINE: A NEW TREATMENT FOR MAJOR DEPRESSIVE DISORDER.EXPERT OPINION ON PHARMACOTHERAPY. VOL. 17. ISSUE 3. P. 421 -431 24 56% 2
9 NAIK, H , CHAN, S , VAKILYNEJAD, M , CHEN, G , LOFT, H , MAHABLESHWARKAR, AR , AREBERG, J , (2016) A POPULATION PHARMACOKINETIC-PHARMACODYNAMIC META-ANALYSIS OF VORTIOXETINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER.BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. VOL. 118. ISSUE 5. P. 344 -355 23 66% 0
10 DUBOVSKY, SL , (2014) PHARMACOKINETIC EVALUATION OF VORTIOXETINE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 10. ISSUE 5. P. 759-766 19 76% 3

Classes with closest relation at Level 1


Rank Class id link
1 11593 MELANCHOLIA//PSYCHOMOTOR DISTURBANCE//PSYCHOMOTOR RETARDATION
2 7952 PINDOLOL//VILAZODONE//5 HT1A RECEPTOR
3 11145 5 HT7 RECEPTOR//5 HT6 RECEPTOR//5 HT6
4 8376 5 HT3 RECEPTOR//5 HT3 RECEPTOR ANTAGONIST//5 HT3
5 7414 TREATMENT RESISTANT DEPRESSION//RESISTANT DEPRESSION//LITHIUM AUGMENTATION
6 27114 BLEEDING ABNORMALITIES//SELECTIVE SEROTONIN REUPTAKE INHIBITORS//ANTICOAGULATION MEDICATION
7 3683 ESCITALOPRAM//VENLAFAXINE//MILNACIPRAN
8 30745 TRIPLE REUPTAKE INHIBITOR//DOV 216 303//TRIPLE UPTAKE INHIBITORS
9 20838 SEROTONIN MODULATED ANTICONSOLIDATION PROTEIN//UMR 7521LN2C//3 2 CARBOXYPIPERAZIN 4 YLPROPYL 1 PHOSPHONIC ACID
10 9777 SEXUAL DYSFUNCTION//HYPERPROLACTINEMIA//GALACTORRHEA

Go to start page